View Item 

Show simple item record

Higher Renal Replacement Therapy Dose Delivery Influences on Drug Therapy
dc.contributor.authorMueller, Bruce A.en_US
dc.contributor.authorPasko, Deborah A.en_US
dc.contributor.authorSowinski, Kevin M.en_US
dc.date.accessioned2010-06-01T21:58:09Z
dc.date.available2010-06-01T21:58:09Z
dc.date.issued2003-09en_US
dc.identifier.citationMueller, Bruce A.; Pasko, Deborah A.; Sowinski, Kevin M. (2003). "Higher Renal Replacement Therapy Dose Delivery Influences on Drug Therapy." Artificial Organs 27(9): 808-814. <http://hdl.handle.net/2027.42/75000>en_US
dc.identifier.issn0160-564Xen_US
dc.identifier.issn1525-1594en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/75000
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12940903&dopt=citationen_US
dc.description.abstractHigher doses of renal replacement therapy have profound effects on pharmacotherapy, yet little research has been conducted in this area. High-volume renal replacement therapies influence both the pharmacokinetic and the pharmacodynamic profiles of all drugs administered to these critically ill patients. Intermittent high-dose “hybrid” hemodialysis therapies remove drugs to a much different degree than standard thrice-weekly hemodialysis, yet pharmacokinetic studies have not been performed in patients receiving these therapies. High-volume continuous renal replacement therapies offer dosing challenges not seen with standard low-dose therapies. This article describes the pharmacokinetic and pharmacodynamic issues presented by high-volume renal replacement therapies. Given the importance that pharmacotherapy has on optimal patient outcomes, a better understanding of the influence that high-volume renal replacement therapy has on drugs is essential if these high volume therapies are to be used successfully in the intensive care unit.en_US
dc.format.extent80774 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Incen_US
dc.rights2003 International Society for Artificial Organsen_US
dc.subject.otherPharmacokineticsen_US
dc.subject.otherPharmacodynamicsen_US
dc.subject.otherRenal Replacement Therapyen_US
dc.subject.otherHemodialysisen_US
dc.titleHigher Renal Replacement Therapy Dose Delivery Influences on Drug Therapyen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum* Clinical Sciences Department, College of Pharmacy, University of Michigan, Ann Arbor, MI;en_US
dc.contributor.affiliationother† School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, IN, U.S.A.en_US
dc.identifier.pmid12940903en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/75000/1/j.1525-1594.2003.07283.x.pdf
dc.identifier.doi10.1046/j.1525-1594.2003.07283.xen_US
dc.identifier.sourceArtificial Organsen_US
dc.identifier.citedreferenceScott MK, Macias WL, Kraus MA, Clark WR, Carfagna MA, Mueller BA. Effects of dialysis membrane on intradialytic vancomycin administration. Pharmacotherapy 1997; 17: 256 – 62.en_US
dc.identifier.citedreferenceScott MK, Mueller BA, Clark WR. Vancomycin mass transfer characteristics of high-flux cellulosic dialysers. Nephrol Dial Transplant 1997; 12: 2647 – 53.en_US
dc.identifier.citedreferenceGilbert DN, Moellering RC Jr, Sande MA. The Sanford Guide to Antimicrobial Therapy, 29 th edition. Hyde Park, VT: Antimicrobial Therapy, Inc., 1999;en_US
dc.identifier.citedreferenceAronoff GR, Berns JA, Brier ME, et al. Drug Prescribing in Renal Failure, Dosing Guidelines for Adults, 4 th edition. Philadelphia, PA: American College of Physicians, 1999.en_US
dc.identifier.citedreferenceJoy MS, Matzke GR, Frye RF, Palevsky PM. Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am J Kidney Dis 1998; 31: 1019 – 27.en_US
dc.identifier.citedreferenceUchino S, Bellomo R, Goldsmith D, et al. Super high flux hemofiltration: a new technique for cytokine removal. Intensive Care Med 2002; 28: 651 – 5.en_US
dc.identifier.citedreferenceCole L, Bellomo R, Journois D, Davenport P, Baldwin I, Tipping P. High-volume haemofiltration in human septic shock. Intensive Care Med 2001; 27: 978 – 86.en_US
dc.identifier.citedreferenceKellum JA, Mehta RL, Angus DC, Palevsky P, Ronco C, ADQI Workgroup. The first international consensus conference on continuous renal replacement therapy. Kidney Int 2002; 62: 1855 – 63.en_US
dc.identifier.citedreferenceBouman CS, Oudemans-Van Straaten HM, Tijssen JG, Zandstra DF, Kesecioglu J. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Crit Care Med 2002; 30: 2205 – 11.en_US
dc.identifier.citedreferenceRonco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomized trial. Lancet 2000; 356: 26 – 30.en_US
dc.identifier.citedreferenceBrause M, Neumann A, Scumacher T, Grabensee B, Heering P. Effect of filtration volume of continous venovenous hemofiltration in the treatment of patients with acute renal failure in intensive care units. Crit Care Med 2003; 31: 841 – 6.en_US
dc.identifier.citedreferenceManns B, Doig CJ, Lee H, et al. Cost of acute renal failure requiring dialysis in the intensive care unit: clinical and resource implications of renal recovery. Crit Care Med 2003; 31: 449 – 55.en_US
dc.identifier.citedreferenceMehta RL, Chertow GM. In critically ill patients with acute renal failure, outcomes, not dollars, should drive modality choice. Crit Care Med 2003; 31: 644 – 6.en_US
dc.identifier.citedreferenceAgarwal R, Cronin RE. Heterogeneity in gentamicin clearance between high-efficiency hemodialyzers. Am J Kidney Dis 1994; 23: 47 – 51.en_US
dc.identifier.citedreferenceMatzke GR, Halstenson CE, Keane WF. Hemodialysis elimination rates and clearance of gentamicin and tobramycin. Antimicrobial Agents Chemother 1984; 25: 128 – 30.en_US
dc.identifier.citedreferenceReetze-Bonorden P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy. Clin Pharmacokinet 1993; 24: 362 – 79.en_US
dc.identifier.citedreferenceSchetz M, Ferdinande P, Van den Berghe G, Verwaest C, Lauwers P. Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med 1995; 21: 612 – 20.en_US
dc.identifier.citedreferenceBrunet S, Leblanc M, Geadah D, Parent D, Courteau S, Cardinal J. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis 1999; 34: 486 – 92.en_US
dc.identifier.citedreferenceMatzke GR, Frye RF, Joy MS, Palevsky PM. Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Antimicrobial Agents Chemother 2000; 44: 1639 – 44.en_US
dc.identifier.citedreferenceKroh UF. Drug administration in critically ill patients with acute renal failure. New Horiz 1995; 3: 748 – 59.en_US
dc.identifier.citedreferenceNicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrobial Agents Chemother 1995; 39: 650 – 5.en_US
dc.identifier.citedreferenceKumar VA, Craig M, Depner TA, Yeun JY. Extended daily dialysis: a new approach to renal replacement for acute renal failure in the intensive care unit. Am J Kidney Dis 2000; 36: 294 – 300.en_US
dc.identifier.citedreferenceCraig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1 – 10.en_US
dc.identifier.citedreferenceGrant EM, Nicolau DP, Nightingale C, Quintiliani R. Clinical considerations regarding the administration of beta-lactam antibiotics by continuous infusion. J Infect Dis Pharmacother 2001; 4: 1 – 13.en_US
dc.identifier.citedreferenceZimmermann AE, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcomes in patients with Gram-positive bacteremia. Pharmacotherapy 1995; 15: 85 – 91.en_US
dc.identifier.citedreferenceBoereboom FT, Ververs FF, Blankestijn PJ, Savelkoul TJ, van Dijk A. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Intensive Care Med 1999; 25: 1100 – 4.en_US
dc.identifier.citedreferenceForrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrobial Agents Chemother 1993; 37: 1073 – 81.en_US
dc.identifier.citedreferenceThomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrobial Agents Chemother 1998; 42: 521 – 7.en_US
dc.identifier.citedreferenceBottoms G, Fessler J, Murphey E, et al. Efficacy of convective removal of plasma mediators of endotoxic shock by continuous veno-venous hemofiltration. Shock 1996; 5: 149 – 54.en_US
dc.identifier.citedreferenceReiter K, D’Intini V, Bordoni V, et al. High-volume hemofiltration in sepsis. Theoretical basis and practical application. Nephron 2002; 92: 251 – 8.en_US
dc.identifier.citedreferenceTetta C, Bellomo R, D’Intini V, et al. Do circulating cytokines really matter in sepsis? Kidney Int 2003; 63: S69 – 71.en_US
dc.identifier.citedreferenceHermsen ED, Ku YM, Guirguis NG. Enhanced clearance of fluconazole during sustained low-efficiency dialysis. Blood Purif 2002; 20: 315.en_US
dc.identifier.citedreferenceTegeder I, Bremer F, Oelkers R, et al. Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration. Antimicrobial Agents Chemother 1997; 41: 2640 – 5.en_US
dc.identifier.citedreferenceTegeder I, Neumann F, Bremer F, Brune K, Lotsch J, Geisslinger G. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Clin Pharmacol Ther 1999; 65: 50 – 7.en_US
dc.identifier.citedreferenceWallis SC, Mullany DV, Lipman J, Rickard CM, Daley PJ. Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. Intensive Care Med 2001; 27: 665 – 72.en_US
dc.identifier.citedreferenceMuhl E, Martens T, Iven H, Rob P, Bruch HP. Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole. Eur J Clin Pharmacol 2000; 56: 671 – 8.en_US
dc.identifier.citedreferenceKroh UF, Lennartz H. Evaluation and first validation study on a simplified drug dosage algorithm for multiple organ failure. Ren Fail 1992; 14: 579 – 85.en_US
dc.identifier.citedreferenceBohler J, Donauer J, Keller F. Pharmacokinetic principles during renal replacement therapy: drugs and dosage. Kidney Int 1999; 56: S24 – 8.en_US
dc.identifier.citedreferenceKeller E. Pharmacokinetics during continuous renal replacement therapy. Int J Artif Organs 1996; 19: 113 – 7.en_US
dc.identifier.citedreferenceMueller BA, Scarim SK, Macias WL. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. Am J Kidney Dis 1993; 21: 172 – 9.en_US
dc.identifier.citedreferenceMacias WL, Mueller BA, Scarim SK. Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance. Clin Pharmacol Ther 1991; 50: 688 – 94.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1525-1594.2003.07283.x.pdf
Size:
78.88KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.